Dan Kemp, Wugen CEO
A stealthy startup is leveraging natural killer cells with 'memory-like' abilities to go after blood cancer and beyond
The promise of next-gen, “off-the-shelf” cell therapies have thoroughly entranced biopharma with the promise of lowering manufacturing costs and potentially challenging dominant checkpoint inhibitors. But …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.